Avidity Partners: 13F holdings, Q2 2026
Emerging, concentrated · SEC EDGAR filings (CIK 0001791827) · Explore on the interactive board
Avidity Partners disclosed 45 US equity positions worth $624.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is DNTH at 32.8% of the reported book, followed by CGON, ORKA. The top ten holdings are 81.9% of the book, and the portfolio behaves like about 6 equal-weight positions. Versus the prior filing it opened 15 new positions, added to 11, reduced 6 and exited 15.
What does Avidity Partners own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 15 new, 11 added, 6 reduced, 15 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 32.8% | $205.1m | 2,104,184 | 0% | held |
| 2 | CGON CG ONCOLOGY INC | Healthcare | 15.9% | $99.4m | 1,398,948 | 9% | added |
| 3 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 11.6% | $72.4m | 760,424 | 0% | held |
| 4 | JBIO JADE BIOSCIENCES INC | 6.1% | $37.8m | 1,700,708 | 21% | added | |
| 5 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 4.5% | $27.9m | 550,000 | 38% | added |
| 6 | CATX PERSPECTIVE THERAPEUTICS INC | 3.4% | $21.5m | 6,299,999 | 4% | added | |
| 7 | AKTS AKTIS ONCOLOGY INC | 2.5% | $15.6m | 484,200 | 3% | added | |
| 8 | PALVELLA THERAPEUTICS INC NE | 1.7% | $10.7m | 70,000 | 0% | held | |
| 9 | MOBIA MED INC | 1.7% | $10.7m | 798,282 | – | new | |
| 10 | RGEN REPLIGEN CORP | Healthcare | 1.7% | $10.6m | 77,800 | 0% | held |
| 11 | IMUX IMMUNIC INC | 1.6% | $10.3m | 669,941 | – | new | |
| 12 | SENS SENSEONICS HLDGS INC | 1.5% | $9.1m | 1,600,000 | – | new | |
| 13 | KPTI KARYOPHARM THERAPEUTICS INC | 1.4% | $9.0m | 924,487 | 99% | added | |
| 14 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 1.1% | $6.8m | 200,000 | -56% | reduced |
| 15 | DXCM DEXCOM INC | Healthcare | 1.1% | $6.7m | 100,000 | 11% | added |
| 16 | TEM TEMPUS AI INC | Healthcare | 1.0% | $6.1m | 105,000 | 320% | added |
| 17 | MDT MEDTRONIC PLC | Healthcare | 0.9% | $5.5m | 70,000 | -30% | reduced |
| 18 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 0.8% | $5.3m | 519,300 | -45% | reduced |
| 19 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.8% | $5.3m | 98,000 | 227% | added |
| 20 | EHC ENCOMPASS HEALTH CORP | Healthcare | 0.7% | $4.2m | 42,000 | 0% | held |
| 21 | TENX TENAX THERAPEUTICS INC | 0.6% | $3.9m | 265,934 | 23% | added | |
| 22 | NVCT NUVECTIS PHARMA INC | 0.6% | $3.7m | 200,000 | – | new | |
| 23 | PODD INSULET CORP | Healthcare | 0.6% | $3.7m | 24,000 | – | new |
| 24 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 0.5% | $3.4m | 80,000 | 33% | added |
| 25 | MSLE SATELLOS BIOSCIENCE INC | 0.5% | $3.0m | 387,769 | 0% | held | |
| 26 | ALMR ALAMAR BIOSCIENCES INC | 0.5% | $3.0m | 110,000 | – | new | |
| 27 | CNTX CONTEXT THERAPEUTICS INC | 0.4% | $2.8m | 4,998,267 | 0% | held | |
| 28 | GILD GILEAD SCIENCES INC | Healthcare | 0.4% | $2.5m | 20,000 | 0% | held |
| 29 | CRL CHARLES RIV LABS INTL INC | Healthcare | 0.4% | $2.3m | 10,000 | – | new |
| 30 | PHAT PHATHOM PHARMACEUTICALS INC | 0.3% | $2.2m | 200,000 | -20% | reduced | |
| 31 | AVALYN PHARMACEUTICALS INC | 0.3% | $2.0m | 60,000 | – | new | |
| 32 | KAILERA THERAPEUTICS INC | 0.3% | $1.8m | 80,000 | – | new | |
| 33 | GMAB GENMAB A/S | Healthcare | 0.2% | $1.4m | 50,000 | 0% | held |
| 34 | NTLA INTELLIA THERAPEUTICS INC | Healthcare | 0.2% | $1.3m | 75,000 | 0% | held |
| 35 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.2% | $1.2m | 80,000 | -30% | reduced |
| 36 | ODD ODDITY TECH LTD | Consumer Defensive | 0.2% | $1.1m | 70,000 | 0% | held |
| 37 | SCYX SCYNEXIS INC | 0.2% | $1.1m | 260,206 | – | new | |
| 38 | EVMN EVOMMUNE INC | 0.2% | $996.8k | 75,000 | – | new | |
| 39 | ABT ABBOTT LABORATORIES | Healthcare | 0.1% | $907.4k | 10,000 | – | new |
| 40 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.1% | $744.8k | 10,000 | – | new |
| 41 | PTON PELOTON INTERACTIVE INC | Consumer Cyclical | 0.1% | $591.0k | 100,000 | -50% | reduced |
| 42 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.1% | $433.2k | 15,000 | – | new |
| 43 | BRIDGEBIO ONCOLOGY THERAPEUT | 0.1% | $334.2k | 43,853 | 0% | held | |
| 44 | SVRA SAVARA INC | Healthcare | 0.0% | $308.0k | 50,000 | – | new |
| 45 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.0% | $124.2k | 6,660 | 0% | held |
What did Avidity Partners sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| IMUX IMMUNIC INC | 28.7% | $7.4m |
| CNC CENTENE CORP | 8.8% | $2.3m |
| SCYX SCYNEXIS INC | 7.4% | $1.9m |
| NTRA NATERA INC | 6.9% | $1.8m |
| ICLR ICON PLC | 6.8% | $1.8m |
| KVUE KENVUE INC ORD | 6.7% | $1.7m |
| HIMS HIMS & HERS HEALTH INC | 6.0% | $1.6m |
| RVMD REVOLUTION MEDICINES INC | 5.6% | $1.5m |
| CORT CORCEPT THERA | 4.7% | $1.2m |
| ABVX ABIVAX SA-ADR | 4.3% | $1.1m |
| UNH UNITEDHEALTH GRP | 4.0% | $1.0m |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | 3.6% | $932.0k |
| AVR ANTERIS TECHNOLOGIES GLOBAL | 3.2% | $832.5k |
| ABUS ARBUTUS BIOPHARMA CORP | 2.2% | $562.5k |
| ACAD ACADIA PHARM | 1.1% | $288.6k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 75.8% |
| Consumer Defensive | 0.2% |
| Consumer Cyclical | 0.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
| Quarter | Positions | Equity value |
|---|---|---|
| Q2 2026 | 45 | $624.4m |
| Q1 2026 | 45 | $493.8m |
| Q4 2025 | 39 | $346.7m |
| Q3 2025 | 43 | $439.4m |
| Q2 2025 | 55 | $498.8m |
| Q1 2025 | 63 | $484.9m |
| Q4 2024 | 61 | $1.0bn |
| Q3 2024 | 81 | $2.0bn |
| Q2 2024 | 85 | $2.4bn |
| Q1 2024 | 87 | $2.8bn |
| Q4 2023 | 72 | $2.6bn |
| Q3 2023 | 83 | $2.5bn |
| Q2 2023 | 93 | $2.9bn |
| Q1 2023 | 83 | $3.0bn |
| Q4 2022 | 84 | $4.3bn |
| Q3 2022 | 96 | $4.6bn |
Earliest filing: Q4 2019 · 27 quarters on file
How concentrated is Avidity Partners's portfolio?
Across every quarter Avidity Partners has filed, its median largest position is 6.2% of the book and its median top-ten weight is 39.7%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 555 completed holding spells, the median lasted 2.0 quarters; 45 positions are still open and their final length is unknown.